Notably, monoclonal PAX8 and CD5 antibodies are useful in differentiating ITTC from poorly differentiated thyroid carcinoma (PDTC) and squamous cell carcinoma (SCC) (43). Here, PAX8 is linked to squamous cell carcinoma.